Rhythm Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Rhythm Pharmaceuticals has a total shareholder equity of $169.8M and total debt of $106.1M, which brings its debt-to-equity ratio to 62.5%. Its total assets and total liabilities are $332.7M and $163.0M respectively.
Key information
62.5%
Debt to equity ratio
US$106.14m
Debt
| Interest coverage ratio | n/a |
| Cash | US$275.85m |
| Equity | US$169.76m |
| Total liabilities | US$162.99m |
| Total assets | US$332.75m |
Recent financial health updates
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Recent updates
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain
Jan 15Financial Position Analysis
Short Term Liabilities: RYTM's short term assets ($308.3M) exceed its short term liabilities ($55.2M).
Long Term Liabilities: RYTM's short term assets ($308.3M) exceed its long term liabilities ($107.8M).
Debt to Equity History and Analysis
Debt Level: RYTM has more cash than its total debt.
Reducing Debt: RYTM's debt to equity ratio has increased from 0% to 62.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYTM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RYTM is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.